USPTO serial 97145978
KNIT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- RIRIE, VERNA BETH
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KNIT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Susan Piascik Christoff
Susan Piascik Christoff COOLEY LLP1299 PENNSYLVANIA AVE. N.W., SUITE 700WASHINGTON, DC 20004United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Health care coordination and consumer health care navigation services for individuals and medical service providers, namely, providing referrals in the field of nephrology; and promoting public interest and awareness of health care treatments for kidney disease | ACTIVE | — |
| 041 | Providing online journals, namely, blogs featuring in the field of health and medical information, kidney health, kidney disease, kidney disease treatments, and the use of artificial intelligence for medical analysis; entertainment, information, and education services, namely, providing podcasts in the field of health and medical information, kidney health, kidney disease, kidney disease treatments, and the use of artificial intelligence for medical analysis; video production in the field of kidney health, kidney disease, kidney disease treatments, and the use of artificial intelligence for medical analysis; arranging and conducting of conferences, symposia, and educational special events in the field of health and medical information, kidney health, kidney disease, kidney disease treatments, and the use of artificial intelligence for medical analysis; Educational services, namely, conducting informal on-line programs in the fields of health and medical information, kidney health, kidney disease, kidney disease treatments, and the use of artificial intelligence for medical analysis, and printable materials distributed therewith | ACTIVE | — |
| 042 | Development of new technology for others in the field of medical devices and medical diagnostic apparatuses; research, development and consultation related thereto in the field of medical devices and medical diagnostic apparatuses through the use of artificial intelligence; laboratory research in the field of kidney diseases and kidney health; medical research services; research and development services in the field of antibodies; providing temporary use of on-line non-downloadable software and software applications using artificial intelligence for medical analysis; testing, analysis, and evaluation of the goods and services of others to determine conformity with certification standards; Providing temporary use of non-downloadable web-based software for use in health care navigation, health care coordination, and health promotion | ACTIVE | — |
| 044 | Medical profile and medical record analysis designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; Providing information in the field of health and medical information, kidney health, kidney disease, kidney disease treatments, and the use of artificial intelligence for medical analysis; Medical profile and medical record analysis designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with kidney, heart, and liver health and kidney, heart, and liver disease; health care coordination services, namely, providing heath care management services in the nature of providing health-related information and care navigation in the form of providing recommended educational resources, provider, and treatment information for the treatment of kidney, heart, and liver health and kidney, heart, and liver disease | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Renalytix AI, Inc.
- Other trademarks owned by Renalytix AI, Inc.
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named KNIT
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 15, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 15, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 2, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 31, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 31, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 31, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 14, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 17, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 17, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 28, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 15, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 15, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 12, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 12, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 12, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 17, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 17, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 17, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 18, 2022 | CEPE | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED | — |
| Apr 18, 2022 | ALIE | ASSIGNED TO LIE | — |
| Apr 15, 2022 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 15, 2022 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 15, 2022 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Mar 30, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 2, 2021 | NWAP | NEW APPLICATION ENTERED | — |